Rct-869-

The RCT-869 demonstrated a favorable safety profile for the investigational product. The most common AEs reported were mild and transient, including headache, nausea, and fatigue. The incidence of AEs was similar between the treatment and placebo groups, with no significant differences in the rates of serious AEs or AEs leading to treatment discontinuation.

The study's primary endpoint was a composite measure of clinical response, which included symptom reduction, quality of life, and functional outcomes. Secondary endpoints included assessments of safety, patient satisfaction, and exploratory analyses of biomarkers. RCT-869-

Future studies should focus on confirming the results of the RCT-869, as well as exploring the optimal dosing regimen, treatment duration, and patient populations that would benefit most from this intervention. The RCT-869 demonstrated a favorable safety profile for